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Abstract
Background:  Many  in vitro studies have shown that adenosine (Ado) can induce vascular
endothelial growth factor (VEGF) mRNA and protein expression and stimulate endothelial
proliferation. In the present study, we seek to determine whether Ado can increase circulating
levels of VEGF protein in the intact human.
Methods: Five outpatients 49.3 ± 6.7 years of age and weighing 88.2 ± 8.5 kg were selected. They
were given a 6 min intravenous infusion of Ado (0.14 mg kg-1 min-1) in conjunction with sestamibi
myocardial perfusion scans. Mean blood pressure (MBP, calculated from systolic and diastolic
values) and heart rate (HR) were determined before Ado infusion and every 2 min for the next 10
min. Plasma VEGF concentrations (ELISA) were determined immediately before Ado infusion and
1 h, 2 h, and 8 h after the infusion.
Results: Plasma VEGF concentration averaged 20.3 ± 2.0 pg ml-1 prior to Ado infusion, and
increased to 62.7 ± 18.1 pg ml-1 at 1 h post- infusion (p < 0.01). VEGF plasma concentration
returned to basal levels 2 h after infusion (23.3 ± 3.4 pg ml-1). MBP averaged 116 ± 7 mmHg and
heart rate averaged 70 ± 7 prior to Ado infusion. MBP decreased by a maximum of ~22% and HR
increased by a maximum of ~17% during the infusion.
Conclusion: We conclude from these preliminary findings that intravenous infusion of adenosine
can increase plasma levels of VEGF in humans.
Background
It is well-established that adenosine is an important phys-
iological regulator for maintaining oxygen homeostasis in
the heart (Berne, 1980; Ely & Berne, 1992). Adenosine for-
mation increases when the oxygen requirements of the
myocardium exceed the oxygen supply, which leads to an
increase in adenosine levels in the tissues (Sparks &
Bardenheuer, 1986; Duessen et al. 1988). The adenosine
released under these conditions is thought to play an
important role in reestablishing a balance between
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oxygen supply and demand (Schrader, 1990) by virtue of
its potent vasodilatory (Stepp et al. 1996) and anti-adren-
ergic effects (Neumann et al. 1995; Dobson et al. 1986).
Mounting evidence suggests that adenosine may also have
a long-term role to increase tissue oxygenation by stimu-
lating angiogenesis (Teuscher & Weildich, 1985; Adair et
al. 1990; Ethier et al. 1993; Marshall, 2001; Adair, 2005).
Adenosine can stimulate endothelial proliferation in vitro
(Meininger et al. 1988; Ethier & Dobson, 1997; Grant et al.
1999; Gu et al. 1999) as well as angioge nesis in a variety
of in vivo models (Adair et al. 1989; Adair et al. 1991;
Adair, 2005). Although the angiogenic effects of adenos-
ine are poorly understood, it is known that adenosine,
mediated by way of adenosine A2 receptors can upregulate
VEGF mRNA and protein expression in many different cell
types (Hashimoto et al. 1994; Takagi et al. 1996; Grant et
al. 1999; Gu et al. 1999; Gu et al. 2000; Feoktistov et al.
2002; Leibovich et al. 2002; Feoktistov et al. 2003; Gar-
dener & Olah, 2003). Numerous investigators have postu-
lated that this adenosine-mediated expression of VEGF
might have a role in mediating adenosine-induced angio-
genesis ; however, it is still not clear whether adenosine
can induce VEGF expression in the intact organism.
In this study, we sought to determine whether adenosine
can increase circulating VEGF protein in humans. The
results show that a short-term intravenous infusion of
adenosine caused the plasma levels of VEGF protein to
increase by about threefold at one hour after the infusion
Results
The intravenous infusion of Ado (0.14 mg kg-1 min-1 for 6
min) caused the plasma levels of VEGF protein to increase
(P1–P5) one hour after the infusion (Figure 1a). However,
the VEGF response to Ado varied greatly among the sub-
jects ranging from a 21% increase (P1, 15.6 pg ml-1 to 18.9
pg ml-1) to a 329% increase (P5, 25.6 pg ml-1 to 110.1 pg
ml-1), as shown in Figure 1b. Plasma VEGF protein levels
averaged 20.3 ± 2.0 pg ml-1 before the infusion, and
increased to an average of 62.7 ± 18.1 pg ml-1 (p < 0.05)
one hour after the infusion. VEGF protein levels returned
to control values by 2 h after the Ado infusion (23.3 ± 3.4
pg ml-1) and remained at control levels at 8 h post- infu-
sion (24.3 ± 7.0 pg ml-1), as shown in Figure 1a.
The infusion of Ado caused MBP to decrease in most of
the subjects (Figure 2), ranging from a 1 mmHg decrease
in P1 (control MBP, 94 mmHg) to a 59 mmHg decrease in
P5 (control MBP, 128 mmHg). This maximum decrease in
MBP occurred after 2 minutes of Ado infusion in two sub-
jects (P2, P3) and after 6 min of infusion in three subjects
(P1, P4, P5). Note on Figure 2 that MBP did not decrease
below 69 mmHg in any of the subjects.
The decrease in MBP was associated with decreases in
both systolic (SBP) and diastolic (DBP) pressures (Table
1). Note also on Table 1 that adenosine increased heart
rate (HR) significantly during the period of infusion. This
increase in HR is typically seen in human subjects infused
with adenosine and is thought to be a reflex response to
the fall in blood pressure.
Effect of adenosine on plasma VEGF protein concentration Figure 1
Effect of adenosine on plasma VEGF protein concentration. 
Adenosine (0.14 mg kg-1 min-1) was infused intravenously for 
6 minutes at 0 h. Panel A: Adenosine caused plasma VEGF 
protein concentration to increase by an average of ~3-fold at 
1 h post-infusion. Plasma VEGF protein levels at 0, 1, 2, and 8 
h were 20.3 ± 2.0, 62.7 ± 18.1, 23.3 ± 3.4, and 24.3 ± 7.0 pg 
ml-1, respectively. Panel B: Adenosine caused plasma levels of 
VEGF protein to increase in all 5 subjects one h after the 
infusion; however, the response was relatively small in two 
subjects. Bars are means ± S.E.M. (n = 5 for each bar). Aster-
isks indicate p < 0.01.
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Discussion
The results have shown that adenosine can increase
plasma levels of VEGF protein in humans. The intrave-
nous infusion of adenosine caused a three-fold increase in
plasma VEGF protein levels one hour after the infusion
(Figure 1a). Previous studies have shown that exogenous
administration of adenosine or adenosine agonists
(Hashimoto et al. 1994; Fischer et al. 1995; Takagi et al.
1996; Pueyo et al. 1998; Grant et al. 1999; Gu et al. 1999;
Grant et al. 2001; Leibovich et al. 2002; Gardener & Olah,
2003; Feoktistov et al. 2003) or upregulation of endog-
enous adenosine (Gu et al. 2000) can enhance VEGF pro-
tein and/or mRNA expression in a variety of cultured cells
(for review, see Adair, 2005). However, the present study
is the first, to our knowledge, that demonstrates that the
infusion of adenosine can increase circulating levels of
VEGF in vivo.
The known cardiovascular effects of adenosine are medi-
ated by the A1 and A2 (subtypes A2A and A2B) receptors (for
review see Shryock & Belardinelli, 1997; Ralevic & Burn-
stock 1998; Rongen et al. 1999). Responses to activation
of the A1 receptor include slowing of the heart and slow-
ing of impulse conduction through the atrioventricular
node, reduction of atrial contractility, inhibition of beta-
adrenergic effects, and vasodilatation (Bryan & Marshall,
1999). Activation of A2  receptors causes (a) vascular
smooth muscle relaxation (Belardinelli et al. 1998; Ngai et
al.  2001; Hinschen et al. 2003), which can lead to
decreases in blood pressure, and (b) induction of VEGF
expression from a variety of cell types (Hashimoto et al.
1994; Pueyo et al. 1998; Grant et al. 1999; Gu et al. 1999;
Leibovich et al. 2002; Gardener & Olah, 2003; Feoktistov
et al. 2003). Recent development of selective agonists and
antagonists for A2 receptor subtypes suggests that vasodil-
atation is mediated by A2A (Shryock & Belardinelli, 1997;
Belardinelli et al. 1998; Rongen et al. 1999) and perhaps
A2B receptors (Ralevic & Burnstock 1998; Ngai et al. 2001;
Hinschen et al. 2003). The A2B receptor subtype appears to
mediate the induction of VEGF protein and mRNA in var-
ious human cell types. Grant et al. (1999) have shown that
activation of the adenosine A2B receptor (but not the A2A
receptor) can increase VEGF mRNA and protein expres-
sion in cultured human retinal endothelial cells. Feoktis-
tov et al. (2003) established that adenosine acting by way
of the A2B receptor can stimulate VEGF expression in
human mast cells. These latter investigators (Feoktistov et
al. 2002) also showed that adenosine can induce VEGF
expression in human microvascular endothelial cells,
where A2B receptors are abundant, but not in human
umbilical vein endothelial cells, which preferentially
express A2A receptors. Therefore, the available data suggest
that adenosine induced vasodilatation and VEGF expres-
sion could be mediated to some extent by similar
receptors.
It is not clear from the present study whether the infusion
of adenosine actually induced the transcription and trans-
lation of VEGF ; however, it is known that both VEGF
mRNA and protein can be induced within a one hour
period of time. Breen et al. (1996) found a fourfold
increase in VEGF mRNA at the termination of a one hour
bout of treadmill exercise in rats. Gu and Adair (1997)
showed that exposing dog myocardial vascular smooth
muscle cells to a hypoxic environment caused a twofold
increase in VEGF protein concentration in the media after
only one hour of exposure to the hypoxic environment.
Therefore, it is conceivable that adenosine could induce
Mean blood pressure (MBP) was calculated from systolic and  diastolic pressures for the 5 patients (P1–P5) Figure 2
Mean blood pressure (MBP) was calculated from systolic and 
diastolicpressures for the 5 patients (P1–P5). MBP was meas-
ured before Ado infusion (time 0), and then every 2 min for 
the next 10 min, except in P3 in which a 10 min MBP was not 
obtained. Ado infusion caused MBP to decrease at some 
point during the infusion in all subjects, but the pressure did 
not decrease below 69 mmHg in any of the subjects.
Table 1: Acute cardiovascular effects of adenosine infusion.
0 min 2 min 4 min 6 min 8 min 10 min
HR 70 ± 3 77 ± 4 81 ± 5* 82 ± 5* 78 ± 4 77 ± 5
SBP 159 ± 12 153 ± 9 144 ± 11 135 ± 9* 155 ± 12 145 ± 7
DBP 94 ± 5 80 ± 5 72 ± 8* 68 ± 9** 81 ± 7 72 ± 6
MBP 116 ± 7 104 ± 6 96 ± 8* 90 ± 9** 106 ± 8 96 ± 3
Heart rate (HR, beats per minute), systolic blood pressure (SBP, 
mmHg), diastolic blood pressure (DBP, mmHg) and mean blood 
pressure (MBP, mmHg) were measured before Ado infusion (0 min) 
and then every 2 min for the next 10 min. MBP was calculated from 
SBP and DBP. Values are means ± S.E.M. (n = 5 at all times, except at 
10 min where n = 4). * indicate p < 0.05. ** indicate p < 0.01.
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VEGF transcription and translation resulting in elevated
plasma levels of VEGF at one hour post infusion. How-
ever, additional studies will be required to determine
whether the increase in circulating VEGF caused by
adenosine did in fact result from adenosine-induced pro-
duction of VEGF.
A possibility that must be considered is that the transient
decrease in blood pressure caused by adenosine leads to
transient hypoxia in the tissues, and that the hypoxia, in
turn, leads to the induction of VEGF expression. Hypoxia
is a well-known stimulus for the induction of VEGF
expression both in vitro and in vivo (for review see Ferrara
& Davis-Smyth, 1997; Ferrara, 2001). However, it seems
unlikely that this indirect induction of VEGF by adenosine
could explain entirely the results of the present study for
the following reasons: (a) adenosine can induce VEGF
mRNA and protein expression in vitro where blood pres-
sure is not an issue, as discussed previously; (b) adenosine
increased the plasma levels of VEGF in two patients in
whom the blood pressure had decreased by less than 15
mmHg, a decrease that should not cause significant per-
fusion problems or hypoxia in the tissues; (c) mean blood
pressure did not fall below 69 mmHg in any of the sub-
jects; and (d) none of the subjects experienced symptoms
suggestive of cerebral hypoxia during the infusion of ade-
nosine. All subjects were supine during the infusion of
adenosine to minimize potential perfusion problems.
Furthermore, adenosine induced vasodilatation would be
expected to improve the distribution of oxygen within a
tissue, also arguing against tissue hypoxia. Therefore, it is
unlikely that the adenosine induced decrease in blood
pressure contributed significantly to the rise in VEGF.
Conclusion
In conclusion, this study provides preliminary data show-
ing that an intravenous infusion of adenosine can increase
plasma levels of VEGF in humans. Additional studies will
be required to determine whether the increase in plasma
VEGF caused by adenosine results from the transcription
and translation of VEGF.
Methods
Subject demographics
The study protocol was approved by the University of Mis-
sissippi Medical Center Internal Review Board. The sub-
jects underwent routine sestamibi myocardial perfusion
scans because of suspected coronary artery disease. They
consisted of one man and four women; mean age was
49.3 ± 6.7 years and mean weight was 88.2 ± 8.5 kg. None
of the subjects had taken caffeine prior to the test, had a
history of asthma or myocardial infarction, or were being
treated with blood pressure medications. Their mean
blood pressure (MBP, auscultatory sphygmomanometry)
prior to testing was 116 ± 7 mmHg (systolic, 159 ± 12
mmHg; diastolic, 94 ± 5 mmHg). MBP was calculated as
the diastolic pressure plus one third of the pulse pressure.
Mean heart rate was 70 ± 3 beats per minute; one patient
(P4) was paced at 66 beats per minute. Also, one individ-
ual (P3) had a history of multiple myeloma and was being
evaluated for kidney transplantation.
Experimental protocol
Adenosine (Adenoscan®, Medco Research, Inc.) was
infused intravenously at 0.14 mg kg-1 min-1 for six minutes
(i.e., total dose was 0.84 mg kg-1). MBP was measured
before the adenosine infusion and then every two minutes
for the next ten minutes. Technetium-99 (sestamibi) was
administered three minutes into the adenosine infusion
and a nuclear scan was performed. The infusion of Ado
was well tolerated by all subjects. There were no signifi-
cant ECG abnormalities during the test and no myocardial
perfusion abnormalities were found. None of the subjects
were diagnosed with cardiovascular disease. Three mL of
blood were collected in EDTA coated tubes before the ade-
nosine infusion and at 1, 2, and 8 h after the adenosine
infusion. The blood samples were centrifuged at 700 g for
5 minutes at 4°C, and plasma was stored at -80°C.
Measurement of VEGF protein
Plasma levels of VEGF were measured in duplicate by
sandwich ELISA (R&D Systems, Minneapolis). In these
assays, the test sample is sandwiched between a mono-
clonal antibody against human recombinant VEGF. A sec-
ond polyclonal antibody against VEGF is conjugated to
horseradish peroxidase and then added to the mixture.
Color develops by addition of hydrogen peroxide and
chromagen tetramethylbenzidine, and the intensity is
measured at 450 nm. VEGF plasma protein levels (pg ml-
1) were calculated using an equation generated from the
regression analysis of standard VEGF concentrations.
Statistical analyses
The results are expressed as means ± standard errors of the
mean (S.E.M.). Differences between the groups (e.g.,
plasma VEGF at various times) were compared using anal-
ysis of variance for repeated measurements and Dunnett's
multiple comparison test (InStat, GraphPad Software,
Inc.).
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